Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Louisa R HoesJ Maxime van Berge HenegouwenHanneke van der WijngaartLaurien J ZeverijnDaphne L van der VeldenJoris van de HaarPaul RoepmanWendy W J de LengAnne M L JansenErik D van WerkhovenVincent van den NoortAlwin D R HuitemaEelke H GortJan Willem B de GrootEmile D KerverDerk Jan de GrootFrans ErdkampLaurens V BeerepootMarieke H J van den Beuken-van EverdingenEgbert F SmitWinette T A van der GraafCarla M L van HerpenMariette LabotsAnn HoebenHans MorreauMartijn Paul LolkemaEdwin CuppenAndré B P van KuilenburgHenk M W VerheulEmile E VoestPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Comprehensive molecular testing in patients with rare cancers may identify treatment opportunities and clinical benefit similar to patients with common cancers. Our findings highlight the importance of access to broad molecular diagnostics to ensure equal treatment opportunities for all patients with cancer.